ArticleScientific reports2026
A comprehensive study integrating bioinformatics analysis and experimental results on HROB as a potential biomarker for the prognosis of lung adenocarcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
HROB, which is a DNA-binding protein linked to various cancers, has an unclear role in lung adenocarcinoma (LUAD). To explore its clinical significance and potential pathogenesis, we analysed RNA-seq data from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) and focused on differential expression, survival impact, functional pathways, and immune infiltration. Our findings revealed that HROB mRNA expression is significantly elevated in LUAD tissues compared with normal lung tissues. High HROB expression is associated with more aggressive tumour characteristics and poorer prognosis of LUAD, with a hazard ratio of 1.815 being observed (P = 0.004), thus suggesting that HROB could serve as an independent prognostic biomarker. The results of the functional enrichment analyses indicated that HROB is involved in cell cycle regulation pathways. Notably, immune infiltration analysis revealed a significant correlation between HROB expression and Th2 cell infiltration (R = 0.626). We also constructed a protein-protein interaction (PPI) network using the STRING database and identified six candidate small-molecule agents that may target HROB. In vitro experiments demonstrated that the knockdown of HROB expression reduces LUAD cell proliferation and invasion while inducing changes in cell cycle progression. Overall, our study establishes HROB as a critical biomarker for LUAD prognosis and highlights its potential role as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.